Quick Answer
Atea Pharmaceuticals, Inc. reported Total Revenue of $351.37 million for fiscal year 2021.
Atea Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $351.37M +622.5% |
$48.63M |
| Revenue (ASC 606) | — | — | — | — | $351.37M +622.5% |
$48.63M |
| Net Income | -$158.35M +6.0% |
-$168.38M -23.9% |
-$135.96M -17.3% |
-$115.91M -195.6% |
$121.19M +1207.1% |
-$10.95M +22.0% |
| Diluted EPS | -$1.94 +3.0% |
-$2.00 -22.7% |
-$1.63 -17.3% |
-$1.39 -201.5% |
$1.37 +368.6% |
-$0.51 +63.3% |
| Total Assets | $315.22M -32.2% |
$464.67M -21.9% |
$594.97M -10.8% |
$666.71M -13.7% |
$772.89M -10.5% |
$863.63M +3812.6% |
| Cash and Equivalents | $95.71M +47.9% |
$64.70M -55.0% |
$143.82M -23.7% |
$188.46M -75.3% |
$764.38M -10.1% |
$850.12M +3824.6% |
| Stockholders Equity | $275.43M -37.2% |
$438.87M -21.0% |
$555.19M -13.3% |
$640.57M -9.8% |
$710.08M +29.6% |
$547.80M +1205.1% |
| R&D Expense | $148.02M +2.7% |
$144.10M +26.1% |
$114.24M +39.4% |
$81.94M -51.0% |
$167.21M +339.7% |
$38.02M +273.9% |
| Operating Income | -$180.89M +6.3% |
-$192.95M -17.5% |
-$164.16M -25.7% |
-$130.65M -194.4% |
$138.38M +1354.6% |
-$11.03M +24.5% |
| Shares Outstanding | 78.13M -7.5% |
84.46M +1.2% |
83.44M +0.2% |
83.29M +0.2% |
83.10M +0.8% |
82.44M +716.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2021 | $32.81M | — | -45.7% |
| Revenue (ASC 606) | September 30, 2021 | $32.81M | — | -45.7% |
| Net Income | September 30, 2025 | -$42.05M | -35.0% | -13.2% |
| Diluted EPS | September 30, 2025 | -$0.53 | -43.2% | -20.5% |
| Total Assets | September 30, 2025 | $342.96M | -30.1% | -12.4% |
| Cash and Equivalents | September 30, 2025 | $77.34M | -21.4% | -11.8% |
| Stockholders Equity | September 30, 2025 | $315.78M | -31.1% | -13.3% |
| R&D Expense | September 30, 2025 | $38.35M | +46.6% | +18.8% |
| Operating Income | September 30, 2025 | -$45.57M | -22.5% | -10.2% |
| Shares Outstanding | September 30, 2025 | 78.13M | -7.5% | -3.7% |
- Atea Pharmaceuticals, Inc. reported Total Revenue of $351.37 million for fiscal year 2021.
- Atea Pharmaceuticals, Inc. showed an increase of +622.5% in Total Revenue compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Revenue (ASC 606) of $351.37 million for fiscal year 2021.
- Atea Pharmaceuticals, Inc. showed an increase of +622.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Net Income of -$158.35 million for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +6.0% in Net Income compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Diluted EPS of $1.94 per share (loss) for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +3.0% in Diluted EPS compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Total Assets of $315.22 million for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed a decrease of -32.2% in Total Assets compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Cash and Equivalents of $95.71 million for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +47.9% in Cash and Equivalents compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Stockholders Equity of $275.43 million for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed a decrease of -37.2% in Stockholders Equity compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported R&D Expense of $148.02 million for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +2.7% in R&D Expense compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Operating Income of -$180.89 million for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +6.3% in Operating Income compared to the prior fiscal year.
- Atea Pharmaceuticals, Inc. reported Shares Outstanding of 78.13 million shares for fiscal year 2025.
- Atea Pharmaceuticals, Inc. showed a decrease of -7.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: